Abstract
To evaluate the association between acyclovir use and survival in patients with advanced human immunodeficiency virus infection, observational data from 1044 persons with AIDS or AIDS-related complex (ARC) and ≤250 CD4 cells/mm3following initiation of zidovudine were analyzed. Of these patients, 336 (32%) received regular acyclovir (≥6 weeks in 2 months). There were no differences in mortality data between acyclovir users and nonusers overall or when analyzed from 1 year after first use of zidovudine, from time of AIDS in those with ARC at enrollment, from patients with AIDS or <100 CD4 cells/mm3at enrollment, or from patients taking acyclovir for up to 10 months. Acyclovir use was associated with increased mortality (relative hazard, 1.28; P =.057) independent of herpesvirus infections and of other characteristics associated with mortality. In this study, the use of acyclovir at doses for treatment of herpes simplex virus infection in combination with zidovudine was not associated with prolonged survival.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 346-352 |
| Number of pages | 7 |
| Journal | Journal of Infectious Diseases |
| Volume | 172 |
| Issue number | 2 |
| DOIs | |
| State | Published - 1995 |
Fingerprint
ASJC Scopus subject areas
- Infectious Diseases
- Immunology and Allergy
- Public Health, Environmental and Occupational Health
- Immunology
Cite this
Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. / Gallant, Joel E.; Moore, Richard D; Keruly, Jeanne C; Richman, Douglas D.; Richman, Richard E.; Chaisson, Richard E.
In: Journal of Infectious Diseases, Vol. 172, No. 2, 1995, p. 346-352.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine
AU - Gallant, Joel E.
AU - Moore, Richard D
AU - Keruly, Jeanne C
AU - Richman, Douglas D.
AU - Richman, Richard E.
AU - Chaisson, Richard E
PY - 1995
Y1 - 1995
N2 - To evaluate the association between acyclovir use and survival in patients with advanced human immunodeficiency virus infection, observational data from 1044 persons with AIDS or AIDS-related complex (ARC) and ≤250 CD4 cells/mm3following initiation of zidovudine were analyzed. Of these patients, 336 (32%) received regular acyclovir (≥6 weeks in 2 months). There were no differences in mortality data between acyclovir users and nonusers overall or when analyzed from 1 year after first use of zidovudine, from time of AIDS in those with ARC at enrollment, from patients with AIDS or <100 CD4 cells/mm3at enrollment, or from patients taking acyclovir for up to 10 months. Acyclovir use was associated with increased mortality (relative hazard, 1.28; P =.057) independent of herpesvirus infections and of other characteristics associated with mortality. In this study, the use of acyclovir at doses for treatment of herpes simplex virus infection in combination with zidovudine was not associated with prolonged survival.
AB - To evaluate the association between acyclovir use and survival in patients with advanced human immunodeficiency virus infection, observational data from 1044 persons with AIDS or AIDS-related complex (ARC) and ≤250 CD4 cells/mm3following initiation of zidovudine were analyzed. Of these patients, 336 (32%) received regular acyclovir (≥6 weeks in 2 months). There were no differences in mortality data between acyclovir users and nonusers overall or when analyzed from 1 year after first use of zidovudine, from time of AIDS in those with ARC at enrollment, from patients with AIDS or <100 CD4 cells/mm3at enrollment, or from patients taking acyclovir for up to 10 months. Acyclovir use was associated with increased mortality (relative hazard, 1.28; P =.057) independent of herpesvirus infections and of other characteristics associated with mortality. In this study, the use of acyclovir at doses for treatment of herpes simplex virus infection in combination with zidovudine was not associated with prolonged survival.
UR - http://www.scopus.com/inward/record.url?scp=0029125606&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029125606&partnerID=8YFLogxK
U2 - 10.1093/infdis/172.2.346
DO - 10.1093/infdis/172.2.346
M3 - Article
VL - 172
SP - 346
EP - 352
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 2
ER -